Autologous T cells are engineered to express a CD19-directed chimeric antigen receptor, enabling them to recognize and kill CD19+ B-lineage cells via cytotoxic mechanisms (e.g., perforin/granzyme and cytokine-mediated killing). This depletes autoreactive B cells, reduces autoantibody production, and aims to reset humoral immunity.